Cytek Biosciences Inc (CTKB)

Current ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020
Total current assets	US$ in thousands	396,446	390,191	384,084	388,647	392,060	422,315	424,821	425,622	454,020	443,859	443,270	439,112	432,052	439,826	216,938	212,537	208,622
Total current liabilities	US$ in thousands	67,663	62,797	52,379	55,566	56,226	58,693	53,591	56,517	49,040	41,494	42,350	42,803	32,160	29,839	28,165	27,764	26,536
Current ratio		5.86	6.21	7.33	6.99	6.97	7.20	7.93	7.53	9.26	10.70	10.47	10.26	13.43	14.74	7.70	7.66	7.86

December 31, 2024 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $396,446K ÷ $67,663K
= 5.86

The current ratio of Cytek Biosciences Inc, which measures the company's ability to cover its short-term liabilities with its short-term assets, has shown fluctuations over the period from December 31, 2020, to December 31, 2024.

The ratio was relatively high at the end of 2020, standing at 7.86, indicating a strong ability to meet short-term obligations. However, the ratio started to decrease gradually in the subsequent quarters but remained above 7. This downward trend continued until the end of September 2021, when the current ratio suddenly spiked to 14.74, indicating a substantial increase in short-term assets relative to short-term liabilities.

Subsequently, the current ratio declined from the peak in September 2021 but remained relatively high through December 2022. This indicates that the company continued to maintain a strong ability to cover its short-term obligations during this period. However, from March 31, 2023, to December 31, 2024, the current ratio experienced a downward trend, dropping from 7.53 to 5.86.

The decreasing trend in the current ratio from 2023 to 2024 may indicate potential liquidity challenges or a shift in the company's short-term asset and liability composition. It would be advisable for stakeholders to closely monitor this trend to ensure that Cytek Biosciences Inc maintains a healthy liquidity position to meet its short-term obligations.